# EDGAR Filing Document

**Accession Number:** 0001976517
**File Stem:** 0000894189-25-015255
**Filing Date:** 2025-11
**Character Count:** 21274
**Document Hash:** 929f89e5a40a00a28237b1daef17570a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000894189-25-015255.hdr.sgml**: 20251125

**ACCESSION NUMBER**: 0000894189-25-015255

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251125

**DATE AS OF CHANGE**: 20251125

**PERIOD START**: 20251231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Roundhill ETF Trust
- **CENTRAL INDEX KEY:** 0001976517

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23887
- **FILM NUMBER:** 251520531

**BUSINESS ADDRESS:**
- **STREET 1:** 154 WEST 14TH STREET
- **STREET 2:** 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
- **BUSINESS PHONE:** 6466615441

**MAIL ADDRESS:**
- **STREET 1:** 154 WEST 14TH STREET
- **STREET 2:** 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011

## Series and Classes Contracts Data

### Roundhill GLP-1 & Weight Loss ETF (Series ID: S000085000)

| Class ID   | Class Name                        | Ticker Symbol   |
|:---|:---|:---|
| C000249863 | Roundhill GLP-1 & Weight Loss ETF | OZEM            |

## Nport-Ex

---

| | | | |
|:---|:---|:---|:---|
| **Roundhill GLP-1 & Weight Loss ETF** | **Roundhill GLP-1 & Weight Loss ETF** | **Roundhill GLP-1 & Weight Loss ETF** | **Roundhill GLP-1 & Weight Loss ETF** |
| **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** | **Schedule of Investments** |
| **September 30, 2025 (Unaudited)** | **September 30, 2025 (Unaudited)** | **September 30, 2025 (Unaudited)** | **September 30, 2025 (Unaudited)** |
| **COMMON STOCKS - 99.8%** | **COMMON STOCKS - 99.8%** | **Shares** | **Value**  |
| **Biotechnology - 34.8%<sup>(a)</sup>** | **Biotechnology - 34.8%<sup>(a)</sup>** | **Biotechnology - 34.8%<sup>(a)</sup>** | |
| Amgen, Inc. | Amgen, Inc. | 4248 | $1198786 |
| Biohaven Ltd. <sup>(b)</sup> | Biohaven Ltd. <sup>(b)</sup> | 44793 | 672343 |
| Gilead Sciences, Inc. | Gilead Sciences, Inc. | 5414 | 600954 |
| Gubra AS | Gubra AS | 13094 | 803019 |
| Innovent Biologics, Inc. <sup>(b)(c)</sup> | Innovent Biologics, Inc. <sup>(b)(c)</sup> | 110000 | 1362912 |
| Metsera, Inc. <sup>(b)(d)</sup> | Metsera, Inc. <sup>(b)(d)</sup> | 25607 | 1340014 |
| Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. | 1704 | 958108 |
| Scholar Rock Holding Corp. <sup>(b)(d)</sup> | Scholar Rock Holding Corp. <sup>(b)(d)</sup> | 24370 | 907539 |
| Structure Therapeutics, Inc. - ADR <sup>(b)(d)</sup> | Structure Therapeutics, Inc. - ADR <sup>(b)(d)</sup> | 58222 | 1630216 |
| Terns Pharmaceuticals, Inc. <sup>(b)</sup> | Terns Pharmaceuticals, Inc. <sup>(b)</sup> | 121455 | 912127 |
| Viking Therapeutics, Inc. <sup>(b)(d)</sup> | Viking Therapeutics, Inc. <sup>(b)(d)</sup> | 59264 | 1557458 |
|  |  |  | 11943476 |
| **Pharmaceuticals - 65.0%<sup>(a)</sup>** | **Pharmaceuticals - 65.0%<sup>(a)</sup>** | **Pharmaceuticals - 65.0%<sup>(a)</sup>** |  |
| AstraZeneca PLC - ADR | AstraZeneca PLC - ADR | 15376 | 1179647 |
| Chugai Pharmaceutical Co. Ltd. | Chugai Pharmaceutical Co. Ltd. | 35600 | 1554314 |
| CSPC Pharmaceutical Group Ltd. | CSPC Pharmaceutical Group Ltd. | 506000 | 609380 |
| Eli Lilly & Co. | Eli Lilly & Co. | 6841 | 5219683 |
| Hanmi Pharm Co. Ltd. | Hanmi Pharm Co. Ltd. | 3945 | 1031905 |
| Novo Nordisk AS - ADR <sup>(d)</sup> | Novo Nordisk AS - ADR <sup>(d)</sup> | 107469 | 5963455 |
| Pfizer, Inc. | Pfizer, Inc. | 53523 | 1363766 |
| Rhythm Pharmaceuticals, Inc. <sup>(b)</sup> | Rhythm Pharmaceuticals, Inc. <sup>(b)</sup> | 6386 | 644922 |
| Roche Holding AG | Roche Holding AG | 5199 | 1698259 |
| Shionogi & Co. Ltd. | Shionogi & Co. Ltd. | 27400 | 480801 |
| United Laboratories International Holdings Ltd. | United Laboratories International Holdings Ltd. | 376000 | 725865 |
| Zealand Pharma AS <sup>(b)</sup> | Zealand Pharma AS <sup>(b)</sup> | 25259 | 1833353 |
|  |  |  | 22305350 |
| **TOTAL COMMON STOCKS** (Cost $35,934,612) | **TOTAL COMMON STOCKS** (Cost $35,934,612) | **TOTAL COMMON STOCKS** (Cost $35,934,612) | 34248826 |
| **SHORT-TERM INVESTMENTS** | **SHORT-TERM INVESTMENTS** | **SHORT-TERM INVESTMENTS** | **SHORT-TERM INVESTMENTS** |
| **INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING - 26.7%** | **INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING - 26.7%** | **Units** | **Value**  |
| Mount Vernon Liquid Assets Portfolio, LLC, 4.27% <sup>(e)</sup> | Mount Vernon Liquid Assets Portfolio, LLC, 4.27% <sup>(e)</sup> | 9173358 | 9173358 |
| **TOTAL INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING** (Cost $9,173,358) | **TOTAL INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING** (Cost $9,173,358) | **TOTAL INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING** (Cost $9,173,358) | 9173358 |
| **MONEY MARKET FUNDS - 0.1%** | **MONEY MARKET FUNDS - 0.1%** | **Shares** | **Value**  |
| First American Government Obligations Fund - Class X, 4.05% <sup>(e)</sup> | First American Government Obligations Fund - Class X, 4.05% <sup>(e)</sup> | 20875 | 20875 |
| **TOTAL MONEY MARKET FUNDS** (Cost $20,875) | **TOTAL MONEY MARKET FUNDS** (Cost $20,875) | **TOTAL MONEY MARKET FUNDS** (Cost $20,875) | 20875 |
| **TOTAL INVESTMENTS - 126.6% (**Cost $45,128,845**)** | **TOTAL INVESTMENTS - 126.6% (**Cost $45,128,845**)** | **TOTAL INVESTMENTS - 126.6% (**Cost $45,128,845**)** | 43443059 |
| Liabilities in Excess of Other Assets - (26.6)% | Liabilities in Excess of Other Assets - (26.6)% | Liabilities in Excess of Other Assets - (26.6)% | (9120533) |
| **TOTAL NET ASSETS - 100.0%** | 0.0% | 0.0% | $34322526 |
| two | two | two | –% |
| Percentages are stated as a percent of net assets. | Percentages are stated as a percent of net assets. | Percentages are stated as a percent of net assets. | –% |

---

ADR - American Depositary Receipt <br> LLC - Limited Liability Company <br> PLC - Public Limited Company

(a) To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those
 industries or sectors.

(b) Non-income producing security.

(c) Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified
 institutional investors. As of September 30, 2025, the value of these securities total $1,362,912 or 4.0% of the Fund's net assets.

(d) All or a portion of this security is on loan as of September 30, 2025. The fair value of these securities was $9,059,694.

(e) The rate shown represents the 7-day annualized yield as of September 30, 2025.

------

#### Summary of Fair Value Disclosure as of September 30, 2025 (Unaudited)
Roundhill GLP-1 & Weight Loss ETF (the "Fund") has adopted fair value accounting standards which establish a definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the period, and expanded disclosure of valuation levels for major security types. These inputs are summarized in the three broad levels listed below. The inputs or valuation methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.

Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and based on the best information available.

The following is a summary of the fair valuation hierarchy of the Fund's securities as of September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **<u>Level 1</u>** | **<u>Level 2</u>** | **<u>Level 3</u>** | **<u>Total</u>** |
| <u>Investments:</u> |  |  |  |  |
|  &nbsp;&nbsp;&nbsp;&nbsp;Common Stocks | $34248826 | $– | $– | $34248826 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Investments Purchased with Proceeds from Securities Lending<sup>(a)</sup> | – | – | – | 9173358 |
|  &nbsp;&nbsp;&nbsp;&nbsp;Money Market Funds | 20875 | – | – | 20875 |
| Total Investments | $34269701 | $– | $– | $43443059 |
| Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. | Refer to the Schedule of Investments for further disaggregation of investment categories. |

---

(a) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair
 value amount of $9,173,358 presented in the table are intended to permit reconciliation of the fair value hierarchy to the amounts listed in the Schedule of Investments.

---

| | | |
|:---|:---|:---|
| **Allocation of Portfolio Holdings by Country as of September 30, 2025** | **Allocation of Portfolio Holdings by Country as of September 30, 2025** | |
| (% of Net Assets) | (% of Net Assets) |  |
| Denmark | $8599827 | 25.0% |
| Japan | 2035115 | 5.9 |
| China | 1972292 | 5.8 |
| Switzerland | 1698259 | 5.0 |
| United Kingdom | 1179647 | 3.4 |
| South Korea | 1031905 | 3.0 |
| Hong Kong | 725865 | 2.1 |
| United States | 26200149 | 76.4 |
| Liabilities in Excess of Other Assets | (9120533) | (26.6) |
|  | $**34322526** | 100.0<br> **%** |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Roundhill ETF Trust

- **b. Investment Company Act file number:** 811-23887

- **c. CIK number of Registrant:** 0001976517

- **d. LEI of Registrant:** 5299005P0GRW4PIQ0W17

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 154 West 14th Street

  - **City:** New York

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10011

  - **Telephone number:** 855-561-5728

**Item A.2. Information about the Series.**

- **a. Name of Series:** Roundhill GLP-1 & Weight Loss ETF

- **b. EDGAR series identifier (if any):** S000085000

- **c. LEI of Series:** 529900AZ7GG1DEFS4J15

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2025-12-31

- **b. Date as of which information is reported:** 2025-09-30

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $43718898.11

**Total Liabilities:** $9396498.58

**Net Assets:** $34322399.53

**Cash Not Reported:** $20896.18

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000249863 | -3.57%               | 6.55%                | 5.43%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-31.18                  | $-1224282.37                               |
| Month 2  | $-73330.88               | $2089843.51                                |
| Month 3  | $-159856.43              | $1993873.12                                |

**Designated Index Information**

- **Index Name:** N/A

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                                      | Title                                              | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Amgen Inc                                 | Amgen Inc                                          | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |      4248 | NS      | $1198785.60   | 3.49%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                           | AstraZeneca PLC                                    | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |     15376 | NS      | $1179646.72   | 3.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc                       | Gilead Sciences Inc                                | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |      5414 | NS      | $600954.00    | 1.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Metsera Inc                               | Metsera Inc                                        | CUSIP: 59267L107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     25607 | NS      | $1340014.31   | 3.90%             |  |  |  | No            |                  1 | On Loan: —       |
| Novo Nordisk A/S                          | Novo Nordisk A/S                                   | CUSIP: 670100205<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |    107469 | NS      | $5963454.81   | 17.37%            |  |  |  | No            |                  1 | On Loan: —       |
| Shionogi & Co Ltd                         | Shionogi & Co Ltd                                  | CUSIP: N/A<br>LEI: 35380049VXDTHZI3DY35       | Long             | EC               | CORP              | JP        |     27400 | NS      | $480801.03    | 1.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Roche Holding AG                          | Roche Holding AG                                   | CUSIP: N/A<br>LEI: 549300U41AUUVOAAOB37       | Long             | EC               | CORP              | CH        |      5199 | NS      | $1698259.41   | 4.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Pfizer Inc                                | Pfizer Inc                                         | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |     53523 | NS      | $1363766.04   | 3.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc             | Regeneron Pharmaceuticals Inc                      | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      1704 | NS      | $958108.08    | 2.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc                | Rhythm Pharmaceuticals Inc                         | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |      6386 | NS      | $644922.14    | 1.88%             |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp                 | Scholar Rock Holding Corp                          | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |     24370 | NS      | $907538.80    | 2.64%             |  |  |  | No            |                  1 | On Loan: —       |
| Structure Therapeutics Inc                | Structure Therapeutics Inc                         | CUSIP: 86366E106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     58222 | NS      | $1630216.00   | 4.75%             |  |  |  | No            |                  1 | On Loan: —       |
| Terns Pharmaceuticals Inc                 | Terns Pharmaceuticals Inc                          | CUSIP: 880881107<br>LEI: 254900S1ZDQMF4MYP709 | Long             | EC               | CORP              | US        |    121455 | NS      | $912127.05    | 2.66%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc                   | Viking Therapeutics Inc                            | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |     59264 | NS      | $1557457.92   | 4.54%             |  |  |  | No            |                  1 | On Loan: —       |
| Mount Vernon Liquid Assets Portfolio, LLC | Mount Vernon Liquid Assets Portfolio, LLC          | CUSIP: N/A<br>LEI: N/A                        | Long             | STIV             | PF                | US        |   9173358 | NS      | $9173357.75   | 26.73%            |  |  |  | No            |                  1 | On Loan: No      |
| Zealand Pharma A/S                        | Zealand Pharma A/S                                 | CUSIP: N/A<br>LEI: 549300ITBB1ULBL4CZ12       | Long             | EC               | CORP              | DK        |     25259 | NS      | $1833352.99   | 5.34%             |  |  |  | No            |                  1 | On Loan: No      |
| UNITED LAB                                | United Laboratories International Holdings Ltd/The | CUSIP: N/A<br>LEI: 2549007JL3XIH77JXN70       | Long             | EC               | CORP              | HK        |    376000 | NS      | $725864.99    | 2.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Hanmi Pharm Co Ltd                        | Hanmi Pharm Co Ltd                                 | CUSIP: N/A<br>LEI: 988400PP10VZVUOFE672       | Long             | EC               | CORP              | KR        |      3945 | NS      | $1031905.49   | 3.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Innovent Biologics Inc                    | Innovent Biologics Inc                             | CUSIP: N/A<br>LEI: 25490058ONL9SCIE1R22       | Long             | EC               | CORP              | CN        |    110000 | NS      | $1362911.93   | 3.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Gubra A/S                                 | Gubra A/S                                          | CUSIP: N/A<br>LEI: 254900T17RRFZONO6W53       | Long             | EC               | CORP              | DK        |     13094 | NS      | $803019.52    | 2.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                            | Eli Lilly & Co                                     | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |      6841 | NS      | $5219683.00   | 15.21%            |  |  |  | No            |                  1 | On Loan: No      |
| CSPC Pharmaceutical Group Ltd             | CSPC Pharmaceutical Group Ltd                      | CUSIP: N/A<br>LEI: 529900M3XQCW234H8O91       | Long             | EC               | CORP              | CN        |    506000 | NS      | $609379.98    | 1.78%             |  |  |  | No            |                  1 | On Loan: No      |
| Chugai Pharmaceutical Co Ltd              | Chugai Pharmaceutical Co Ltd                       | CUSIP: N/A<br>LEI: 529900T9LAII161DCN95       | Long             | EC               | CORP              | JP        |     35600 | NS      | $1554313.57   | 4.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Biohaven Ltd                              | Biohaven Ltd                                       | CUSIP: N/A<br>LEI: N/A                        | Long             | EC               | CORP              | US        |     44793 | NS      | $672342.93    | 1.96%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-11-24

**Name of Applicant:** Roundhill ETF Trust

**Signature:** /s/ Justin Katz

**Name of Signer:** Justin Katz

**Title:** Vice President, Operations